# A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct06387069/  
OnCo record `nct06387069` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing HMPL-306 in acute myeloid leukaemia, now recruiting.

## Summary

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukaemia is a phase 3 interventional study registered as NCT06387069, led by Hutchmed, and recruiting on the registry. Official title: A Multicenter, Randomised, Open-Label, Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-306 vs. Salvage Chemotherapy Regimens in Patients With IDH1- and IDH2-mutated Relapsed/Refractory Acute Myeloid Leukaemia (R/R AML). Planned enrolment is 316 participants (estimated). The study started in 2024-04-26 and primary completion is expected in 2028-12-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06387069
- Phase: 3
- Setting: A Multicenter, Randomized, Open-Label, Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-306 vs. Salvage Chemotherapy Regimens in Patients With IDH1- and IDH2-mutated Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Sponsor: Hutchmed
- Enrolled: 316

## Sources

- ClinicalTrials.gov NCT06387069: https://clinicaltrials.gov/study/NCT06387069

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [IDH1- and IDH2-mutated acute myeloid leukaemia](https://onco.cc/cancers/aml-idh/)
- drugs: [HMPL-306](https://onco.cc/drugs/hmpl-306/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)

---
JSON: https://onco.cc/api/v1/entities/nct06387069.json